Now Online: Ecraid Annual Report 2025

In the past four years, Ecraid has rapidly expanded its research network and service offering, supporting industry- and investigator-driven research on infectious diseases. Today, it provides a full breadth of infectious diseases clinical studies – both observational and interventional – in different phases, and a high quality 'warm-base' research network capable of execute trials faster and more efficiently. 

For Ecraid, 2025 marked the transition towards a sustainable future without funding from ECRAID-Base. Despite facing several challenges, the organisation achieved a revenue growth of 13.4% and a small operating margin. 

Ecraid is financially sustainable and continues to attract growing interest from both academic and industry partners. Four years after its founding, Ecraid has established itself as a trusted name in infectious disease research. This milestone is a testament to the dedication, expertise, and collaborative spirit of our young, international team.